食品研究与开发
食品研究與開髮
식품연구여개발
FOOD RESEARCH AND CEVELOPMENT
2015年
3期
110-114
,共5页
酸枣仁皂苷A%药动学%高效液相色谱-质谱串联%生物利用度
痠棘仁皂苷A%藥動學%高效液相色譜-質譜串聯%生物利用度
산조인조감A%약동학%고효액상색보-질보천련%생물이용도
Jujuboside A%pharmacokinetic%HPLC-MS/MS%bioavailability
建立高效液相色谱-质谱串联（HPLC-MS/MS）法检测大鼠血浆中酸枣仁皂苷A的含量，并应用于药动学研究。大鼠静注（4 mg/kg）或灌胃（20 mg/kg）给药，不同时间取血，血浆样品经处理后，采用HPLC-MS/MS法测定酸枣仁皂苷A含量，色谱柱为Waters YMCTM ODS-AQ S-5120A（2.0×100 mm）分析柱，以电喷雾离子化串联质谱（ESI）及多反应监测扫描模式（MRM）进行检测，流动相为甲醇-水（0.1%甲酸）=50∶50，流速为0.3 mL/min，柱温为30℃，根据测定结果求算药物的药动学参数。酸枣仁皂苷A在40 ng/mL~4000 ng/mL的浓度范围内线性关系良好（r2=0.9991），各浓度水平的精密度及稳定性的RSD均小于15%，提取回收率均大于85%。大鼠注射给药后主要药动学参数分别为Ke 0.28/h，t1/22.55 h，AUC0→t 2839.89 h·ng/mL，AUC0→∞3201.51 h·ng/mL，灌胃给药后主要药动学参数分别为Ke 0.51/h，t1/21.35 h，AUC0→t 206.02 h·ng/mL，AUC0→∞211.13 h·ng/mL。经计算，酸枣仁皂苷A在大鼠体内的生物利用度为1.32%。本试验所建立的检测方法快速简便、精密度好、灵敏度高及稳定性好，适用于酸枣仁皂苷A在大鼠体内血药浓度测定及药代动力学的研究。
建立高效液相色譜-質譜串聯（HPLC-MS/MS）法檢測大鼠血漿中痠棘仁皂苷A的含量，併應用于藥動學研究。大鼠靜註（4 mg/kg）或灌胃（20 mg/kg）給藥，不同時間取血，血漿樣品經處理後，採用HPLC-MS/MS法測定痠棘仁皂苷A含量，色譜柱為Waters YMCTM ODS-AQ S-5120A（2.0×100 mm）分析柱，以電噴霧離子化串聯質譜（ESI）及多反應鑑測掃描模式（MRM）進行檢測，流動相為甲醇-水（0.1%甲痠）=50∶50，流速為0.3 mL/min，柱溫為30℃，根據測定結果求算藥物的藥動學參數。痠棘仁皂苷A在40 ng/mL~4000 ng/mL的濃度範圍內線性關繫良好（r2=0.9991），各濃度水平的精密度及穩定性的RSD均小于15%，提取迴收率均大于85%。大鼠註射給藥後主要藥動學參數分彆為Ke 0.28/h，t1/22.55 h，AUC0→t 2839.89 h·ng/mL，AUC0→∞3201.51 h·ng/mL，灌胃給藥後主要藥動學參數分彆為Ke 0.51/h，t1/21.35 h，AUC0→t 206.02 h·ng/mL，AUC0→∞211.13 h·ng/mL。經計算，痠棘仁皂苷A在大鼠體內的生物利用度為1.32%。本試驗所建立的檢測方法快速簡便、精密度好、靈敏度高及穩定性好，適用于痠棘仁皂苷A在大鼠體內血藥濃度測定及藥代動力學的研究。
건립고효액상색보-질보천련（HPLC-MS/MS）법검측대서혈장중산조인조감A적함량，병응용우약동학연구。대서정주（4 mg/kg）혹관위（20 mg/kg）급약，불동시간취혈，혈장양품경처리후，채용HPLC-MS/MS법측정산조인조감A함량，색보주위Waters YMCTM ODS-AQ S-5120A（2.0×100 mm）분석주，이전분무리자화천련질보（ESI）급다반응감측소묘모식（MRM）진행검측，류동상위갑순-수（0.1%갑산）=50∶50，류속위0.3 mL/min，주온위30℃，근거측정결과구산약물적약동학삼수。산조인조감A재40 ng/mL~4000 ng/mL적농도범위내선성관계량호（r2=0.9991），각농도수평적정밀도급은정성적RSD균소우15%，제취회수솔균대우85%。대서주사급약후주요약동학삼수분별위Ke 0.28/h，t1/22.55 h，AUC0→t 2839.89 h·ng/mL，AUC0→∞3201.51 h·ng/mL，관위급약후주요약동학삼수분별위Ke 0.51/h，t1/21.35 h，AUC0→t 206.02 h·ng/mL，AUC0→∞211.13 h·ng/mL。경계산，산조인조감A재대서체내적생물이용도위1.32%。본시험소건립적검측방법쾌속간편、정밀도호、령민도고급은정성호，괄용우산조인조감A재대서체내혈약농도측정급약대동역학적연구。
To establish a method for the determination of the concentration of Jujuboside A (JuA) in rat plasma by liquid chromatography-mass/mass spectrometry (HPLC-MS/MS), and study its pharmacokinetics. The rats were intravenously (4 mg/kg) or oral (20 mg/kg) administrated JuA. Blood samples were drawn from the palpebra at different stages. The concentrations of JuA in the plasma were determined by the HPLC-MS/MS method. Chromatographic separation was carried out with a security guard Waters YMCTM ODS-AQ S-5 120A (2.0 ×100 mm) (Waters, USA). HPLC-MS/MS was performed on a triple-quadrupole mass spectrometry equipped with electrospray ionization (ESI) and negative multiple reaction monitoring (MRM). The mobile phase consisted of methanol-water-formic acid (50∶50∶0.1), delivered at the flow rate of 0.3 mL/min under 30℃. The method was linear over the concentration range of 40 ng/mL-4 000 ng/mL (r2=0.999 1). The relative standard deviations of the assay were less than 15.0%for the low, and the recovery of the method was more than 85 %. The pharmacokinetic parameters were as follows: Ke 0.28/h,t1/2 2.55 h,AUC0→t 2 839.89 h·ng/mL, AUC0→∞3 201.51 h·ng/mL in rat with intravenous administration, and Ke 0.51/h,t1/21.35 h,AUC0→t 206.02 h·ng/mL, AUC0→∞211.13 h·ng/mL in rat with oral administration. The bioavailability of JuA was 1.32%. The developed method was successfully applied to the estimation of the pharmacokinetic parameters of JuA.
